Clinical trials in chronic myeloid leukemia

• Verfasst von: Saußele, Susanne [VerfasserIn]
• Verfasst von: Pfirrmann, Markus [VerfasserIn]
• Titel: Clinical trials in chronic myeloid leukemia
• Verf.angabe: Susanne Saussele, Markus Pfirrmann
• E-Jahr: 2012
• Jahr: 16 March 2012
• Umfang: 7 S.
• Fussnoten: Gesehen am 17.09.2018
• Titel Quelle: Enthalten in: Current hematologic malignancy reports
• Ort Quelle: Philadelphia, Pa. : Current Science, 2006
• Jahr Quelle: 2012
• Band/Heft Quelle: 7(2012), 2, Seite 109-115
• ISSN Quelle: 1558-822X
• DOI: doi:10.1007/s11899-012-0118-1
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Chronic myeloid leukemia
• Sach-SW: Clinical trials
• Sach-SW: Competing risk
• Sach-SW: Composite endpoints
• Sach-SW: Cumulative incidence
• Sach-SW: Cure
• Sach-SW: Cytogenetic remission (response)
• Sach-SW: Dasatinib
• Sach-SW: Imatinib
• Sach-SW: Molecular remission (response)
• Sach-SW: Nilotinib
• Sach-SW: Overall survival
• Sach-SW: Progression-free survival
• Sach-SW: Stopping
• Sach-SW: TKI
• K10plus-PPN: 1581034539

Abstract

The introduction of the tyrosine kinase inhibitor (TKI) imatinib in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) has substantially improved the outcome of CML patients. Despite the positive results, problems and questions remained. This was the rationale to setup trials for treatment optimization, where imatinib was administered in higher dose and/or in combination with other therapy but where also new and potentially more efficacious second-generation TKI, nilotinib and dasatinib, were investigated. This review summarizes data of recently published first-line studies with the standard treatment imatinib 400 mg as one study arm. Results of randomized comparisons to higher-dose imatinib treatment, nilotinib or dasatinib are discussed. With regard to outcome interpretation, general aspects on statistical issues and endpoint definitions are put into focus. Considering decidedly increased longevity thanks to TKI treatment, future research should include the evaluation of the quality of life (QoL). Relating also to QoL, safe ways of drug discontinuation need to be investigated.